Follow Krystal Biotech to never miss an important update.
The company reported earnings of $1.79 per share, which was better than the $1.70 analysts expected. Revenue hit about $119 million for the quarter, driven entirely by Vyjuvek, a gel that treats a rare skin disease by delivering functional genes directly to wounds. Since its launch about a year ago, the therapy has brought in nearly $1 billion in total sales.
This performance is important because it shows the company is successfully transitioning from a research firm into a profitable business. With $1.1 billion in cash on hand, Krystal has enough money to fund its next set of goals without needing to borrow. These goals include launching Vyjuvek in Spain and Italy later this year and testing whether its gene-delivery technology works for lung and eye diseases.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
S&P Dow Jones Indices announced that Krystal Biotech will become a member of the S&P MidCap 400. This index tracks 400 companies that are larger than small-caps but not yet giant corporations.
Joining an index like this is a milestone that reflects the company's growing size and steady profits. It also matters for the stock price because many mutual funds and exchange-traded funds are required to own every stock in the index. This creates a new, permanent group of buyers for the shares.
Source: PRNewsWire
Jefferies raised its price target to $474, suggesting the stock could rise significantly from its current level. This move reflects growing optimism about how much cash the company can generate from its skin disease therapy and its potential to expand into other treatments. While target prices are just estimates from one firm, a double-digit increase like this shows that professional analysts see the business becoming more valuable as it scales.
Source: Jefferies
The company has a very consistent track record of beating analyst expectations, which suggests management is disciplined about the goals they set and then clear them.
| Expectation | |
|---|---|
| EPS | $1.86 |
| Revenue | $129M |
Follow Krystal Biotech to get the latest and most important updates.
Follow KRYS